Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease

Last updated: November 23, 2021
Sponsor: First Affiliated Hospital of Fujian Medical University
Overall Status: Active - Recruiting

Phase

2

Condition

Dementia

Memory Loss

Alzheimer's Disease

Treatment

N/A

Clinical Study ID

NCT04926272
MRCTA, ECFAH of FMU [2021]130
  • Ages 18-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD. 18F-92 molecular probe is a novel molecularly targeted imaging agent, which can rapidly penetrate the blood-brain barrier and has high affinity and selectivity for Aβ protein. In this study, 18F-92 PET/CT was used to monitor the regional distribution and the degree of deposition in patients with Alzheimer's disease, and compared with clinical symptoms (neuropsychometry) to evaluate its application value in the diagnosis of AD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients or their families complain of significant memory impairment;
  • Objective memory impairment (e.g., tests of article identification, recall, delayedmemory);
  • Meets Alzheimer's criteria for DSMIV and NINCDS-ADRDA;
  • Be able to obtain complete diagnosis and treatment records and be able to carry outlong-term follow-up;
  • Signed written consent.

Exclusion

Exclusion Criteria:

  • Nervous system diseases: including brain tumors, craniocerebral trauma, multiplesclerosis, epilepsy, etc.;
  • Psychiatric disorders: including anxiety disorder, affective disorder, severepsychosis, or drug-induced psychosis;
  • Pregnancy or lactation.

Study Design

Total Participants: 50
Study Start date:
July 01, 2021
Estimated Completion Date:
July 01, 2024

Study Description

Healthy volunteers as well as patients meeting Alzheimer's criteria will be recruited for this study.

We will use PET/CT imaging technology to scan each participant's whole body or head and collect image data for analysis to evaluate the distribution and metabolism of 18F-92 in the subject's body. Time from drug injection to scan completion is approximately 1 hour.

Connect with a study center

  • Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian 350005
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.